BNT-111 is under clinical development by BioNTech and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect BNT-111’s likelihood of approval (LoA) and phase transition for Melanoma took place on 07 Dec 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their BNT-111 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

BNT-111 overview

BNT-111 is under development for the treatment of cutaneous melanoma. The therapeutic candidate is developed as adjuvant therapy and administered through intravenous route. The drug candidate comprises tetravalent RNA-lipoplex construct targeting four tumor-associated antigens including cancer/testis antigen 1, melanoma associated antigen 3, tyrosinase and putative tyrosine-protein phosphatase TPTE. It is developed based on messenger RNA (mRNA) therapeutics ((FixVac platform) technology.

BioNTech overview

BioNTech is a biotechnology company that develops immunotherapies for cancer and infectious diseases. It is investigating mRNA therapeutics, engineered cell therapies, antibodies and small molecule immunomodulators to treat advanced melanoma, solid tumors, non-small cell lung cancer (NSCLC), prostate, head and neck, ovarian, pancreatic and triple negative breast cancer. The company is also evaluating treatments for HIV, tuberculosis, influenza and covid-19. BioNTech utilizes FixVac and iNeST technology platforms to discover and develop cancer immunotherapies targeting antigens and neoantigens. It works in partnership with Genentech Inc, Eli Lilly and Co, Genmab AS, and other biopharmaceutical companies to develop its pipeline products. BioNTech is headquartered in Mainz, Rhineland-Palatinate, Germany.

Quick View BNT-111 LOA Data

Report Segments
  • Innovator
Drug Name
  • BNT-111
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: BioNTech
  • Originator: University Medical Center of Johannes Gutenberg University Mainz and BioNTech
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.